Century Therapeutics (IPSC) Total Liabilities (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Total Liabilities data on file, last reported at $61.8 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 17.77% year-over-year to $61.8 million in Q1 2026; TTM through Mar 2026 was $61.8 million, a 17.77% decrease from a year earlier, with the FY2025 full-year figure at $64.8 million, down 66.24% from the prior year.
• Total Liabilities for Q1 2026 stood at $61.8 million, down from $64.8 million in the prior quarter.
• Over the last five years, Total Liabilities for IPSC reached as high as $194.3 million in Q2 2024 and fell as low as $61.8 million in Q1 2026.
• Historically, Total Liabilities has averaged $147.1 million across 5 years, with a median of $174.6 million in 2022.
• Across the five-year window, Total Liabilities soared 346.81% in 2022 and tumbled 66.24% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $183.8 million in 2022, then decreased by 4.28% to $175.9 million in 2023, then increased by 9.04% to $191.9 million in 2024, then tumbled by 66.24% to $64.8 million in 2025, then slipped by 4.57% to $61.8 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $61.8 million in Q1 2026, $64.8 million in Q4 2025, and $68.4 million in Q3 2025.